Showing results (1051-1060 of 5,692) with videos related to
Sort By:
Pageof 570
The Oncologist|January 1, 2008
Review: side effects of approved molecular targeted therapies in solid cancersChristian Widakowich, Gilberto de Castro, Evandro de Azambuja, et al.The Oncologist|March 10, 2017
Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical ImplicationsAlba A Brandes, Enrico Franceschi, Alexandro Paccapelo, et al.The Oncologist|March 19, 2017
Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast CancerVirginia G Kaklamani, William J GradisharThe Oncologist|March 19, 2017
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate CancerXiao X Wei, Andrew C Hsieh, Won Kim, et al.The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.The Oncologist|May 7, 2014
Molecular tumor board: the University of California-San Diego Moores Cancer Center experienceMaria Schwaederle, Barbara A Parker, Richard B Schwab, et al.The Oncologist|May 14, 2014
Adjuvant therapy in early-stage endometrial cancer: a systematic review of the evidence, guidelines, and clinical practice in the U.SNawar A Latif, Ashley Haggerty, Stephanie Jean, et al.The Oncologist|May 14, 2014
Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient careAxel Grothey, Suzanne George, Eric van Cutsem, et al.The Oncologist|March 28, 2019
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell LymphomaNicholas C Richardson, Yvette L Kasamon, Haiyan Chen, et al.The Oncologist|March 28, 2019
Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A ReviewNagla Abdel Karim, Karen KellyPageof 570